Matrix metalloproteinases: Biologic activity and clinical implications

被引:1332
作者
Nelson, AR
Fingleton, B
Rothenberg, ML
Matrisian, LM
机构
[1] Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Med Ctr, Dept Hematol Oncol, Nashville, TN 37232 USA
[3] Vanderbilt Univ, E Bronson Ingram Canc Ctr, Nashville, TN USA
关键词
D O I
10.1200/JCO.2000.18.5.1135
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor progression is a compiler, multistage process by which a normal cell undergoes genetic changes that result in phenotypic alterations and the acquisition of the ability to spread and colonize distant sites in the body. Although many factors regulate malignant tumor growth and spread, interactions between a tumor and its surrounding microenvironment result in the production of important protein products that are crucial to each step of tumor progression. The matrix metalloproteinases (MMPs) are a family of degradative enzymes with clear links to malignancy. These enzymes are associated with tumor cell invasion of the basement membrane and stroma, brood vessel penetration, and metastasis. They have more recently been implicated In primary and metastatic tumor growth and angiogenesis, and they may even have a role in tumor promotion. This review outlines our current understanding of the MMP family, including the association of particular MMPs with malignant phenotypes and the role of MMPs in specific steps of the metastatic cascade. As scientific understanding of the MMPs has advanced, therapeutic strategies that capitalize on blocking the enzymes have rapidly developed. The preclinical and clinical evolution of the synthetic MMP inhibitors (MMPIs) is also examined, with the discussion encompassing important methodologic issues associated with determining clinical efficacy of MMPIs and other novel therapeutic agents. J Clin Oncol 18:1135-1149, (C) 2000 by American Society of Clinical Oncology.
引用
收藏
页码:1135 / 1149
页数:15
相关论文
共 158 条
  • [1] ADAMS M, 1998, P AN M AM SOC CLIN, V17, pA217
  • [2] Ahmad A, 1998, AM J PATHOL, V152, P721
  • [3] TNF-α converting enzyme (TACE) is inhibited by TIMP-3
    Amour, A
    Slocombe, PM
    Webster, A
    Butler, M
    Knight, CG
    Smith, BJ
    Stephens, PE
    Shelley, C
    Hutton, M
    Knäuper, V
    Docherty, AJP
    Murphy, G
    [J]. FEBS LETTERS, 1998, 435 (01) : 39 - 44
  • [4] ANDERSON IC, 1995, CANCER RES, V55, P4120
  • [5] Anderson IC, 1996, CANCER RES, V56, P715
  • [6] SERUM METALLOPROTEINASES AND THEIR INHIBITORS - MARKERS FOR MALIGNANT POTENTIAL
    BAKER, T
    TICKLE, S
    WASAN, H
    DOCHERTY, A
    ISENBERG, D
    WAXMAN, J
    [J]. BRITISH JOURNAL OF CANCER, 1994, 70 (03) : 506 - 512
  • [7] BARSKY SH, 1983, LAB INVEST, V49, P140
  • [8] A NOVEL METALLOPROTEINASE GENE SPECIFICALLY EXPRESSED IN STROMAL CELLS OF BREAST CARCINOMAS
    BASSET, P
    BELLOCQ, JP
    WOLF, C
    STOLL, I
    HUTIN, P
    LIMACHER, JM
    PODHAJCER, OL
    CHENARD, MP
    RIO, MC
    CHAMBON, P
    [J]. NATURE, 1990, 348 (6303) : 699 - 704
  • [9] Beattie GJ, 1998, CLIN CANCER RES, V4, P1899
  • [10] DIRECT EVIDENCE LINKING EXPRESSION OF MATRIX METALLOPROTEINASE-9 (92-KDA GELATINASE/COLLAGENASE) TO THE METASTATIC PHENOTYPE IN TRANSFORMED RAT EMBRYO CELLS
    BERNHARD, EJ
    GRUBER, SB
    MUSCHEL, RJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (10) : 4293 - 4297